BioSpace News Archive

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors in immuno-oncology, announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.

Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, announced that the Japan UPSC UENO Patent Office has issued a patent, No. 7075594, to Aruna Bio and the University of Georgia Research Foundation allowing broad claims on the composition of neural exosomes and their use as a therapeutic for neurological diseases and disorders.

Tessa Therapeutics Ltd. announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced that it has commenced an underwritten public offering of $125 million of shares of its common stock.

Centogene N.V. announced that it has expanded its long-standing PYRUKYND® partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases.

Zhongchao Inc. announced its MDMOOC platform launched online training course titled “Disease Prevention and Distribution Quality Management,” to staffs in various departments for diseases control and prevention, in order to improve their skillsets and efficiency in vaccination management as well as diseases control and prevention.

Mallinckrodt plc announced that it expects to complete its reorganization process, emerge from Chapter 11 and complete the Irish Examinership proceedings in the coming days.

Merck, known as MSD outside the United States and Canada, announced the U.S. Food and Drug Administration has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA for the adjuvant treatment of patients with stage IB, II or IIIA non-small cell lung cancer following complete surgical resection.

Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer’s disease, announced that is has joined Dementias Platform UK as a corporate partner.

ProVerum Limited announced the commencement of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a nitinol expander designed to gently re-shape the enlarged prostate and alleviate the symptoms caused by BPH.